Functionalized Phenylbenzamides Inhibit Aquaporin-4 Reducing Cerebral Edema and Improving Outcome in Two Models of CNS Injury

Cerebral edema in ischemic stroke can lead to increased intracranial pressure, reduced cerebral blood flow and neuronal death. Unfortunately, current therapies for cerebral edema are either ineffective or highly invasive. During the development of cytotoxic and subsequent ionic cerebral edema water...

Full description

Saved in:
Bibliographic Details
Published inNeuroscience Vol. 404; pp. 484 - 498
Main Authors Farr, George W., Hall, Christopher H., Farr, Susan M., Wade, Ramon, Detzel, Joshua M., Adams, Amielia G., Buch, Jasen M., Beahm, Derek L., Flask, Christopher A., Xu, Kui, LaManna, Joseph C., McGuirk, Paul R., Boron, Walter F., Pelletier, Marc F.
Format Journal Article
LanguageEnglish
Published United States Elsevier Ltd 15.04.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cerebral edema in ischemic stroke can lead to increased intracranial pressure, reduced cerebral blood flow and neuronal death. Unfortunately, current therapies for cerebral edema are either ineffective or highly invasive. During the development of cytotoxic and subsequent ionic cerebral edema water enters the brain by moving across an intact blood brain barrier and through aquaporin-4 (AQP4) at astrocyte endfeet. Using AQP4-expressing cells, we screened small molecule libraries for inhibitors that reduce AQP4-mediated water permeability. Additional functional assays were used to validate AQP4 inhibition and identified a promising structural series for medicinal chemistry. These efforts improved potency and revealed a compound we designated AER-270, N-[3,5-bis (trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide. AER-270 and a prodrug with enhanced solubility, AER-271 2-{[3,5-Bis(trifluoromethyl) phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, improved neurological outcome and reduced swelling in two models of CNS injury complicated by cerebral edema: water intoxication and ischemic stroke modeled by middle cerebral artery occlusion. •High throughput screening of small molecule libraries reveals an inhibitor of Aquaporin-4.•Medicinal chemistry leads to development of AER-270 and IV prodrug AER-271, selective partial antagonist of Aquaporin-4.•Aquaporin-4 inhibitor AER-270 prevents cerebral edema and improves survival in a mouse model of water intoxication.•Aquaporin-4 inhibitor AER-271 reduces cerebral edema and improves neurological outcomes in rodent ischemic stroke models.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
AUTHOR CONTRIBUTION STATEMENT
M.F.P., W.F.B., P.R.M., G.W.F. and J.C.L. conceived the study. G.W.F., C.H.H., S.M.F., J.C.L., K.X., C.A.F., P.R.M., W.F.B and M.F.P. contributed to experimental design. M.F.P. and S.M.F. performed high-throughput screening. M.F.P., J.M.D. and A.G.A. performed video microscopy and western blotting. D.L.B., M.F.P. and C.H.H. performed cell volume cytometry assays. M.F.P. and C.H.H. performed light scattering assays. P.R.M designed medicinal chemistry and prodrug formulation. G.W.F., C.H.H., S.M.F. and M.F.P. performed water intoxication model. G.W.F. and S.M.F. performed pharmacokinetic assays. G.W.F., C.H.H. and S.M.F. performed mouse MCAo model. G.W.F., C.H.H., S.M.F. and R.W. performed rat MCAo model. G.W.F., C.H.H., S.M.F., J.M.D., J.M.B., P.R.M. and M.F.P. performed data analysis. G.W.F., P.R.M. and M.F.P. contributed to writing the manuscript. All authors read, edited and approved the final manuscript.
ISSN:0306-4522
1873-7544
DOI:10.1016/j.neuroscience.2019.01.034